SCHEMBL12417073

SCHEMBL12417073

CCOc1ccc(/N=C/c2c(OCC)ccc3ccccc23)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.55
▸ KDM4E B2RXH2 4/20 0.55
▸ MAOB P27338 1/20 0.55
▸ KMT2A Q03164 7/20 0.54
▸ MEN1 O00255 6/20 0.54
▸ MAPT P10636 5/20 0.54
▸ GAA P10253 3/20 0.54
▸ TDP1 Q9NUW8 2/20 0.54
▸ LMNA P02545 1/20 0.54
▸ HPGD P15428 4/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ PKM P14618 1/20 0.53
▸ CASP3 P42574 1/20 0.53
▸ SENP7 Q9BQF6 1/20 0.53
▸ SENP6 Q9GZR1 1/20 0.53
▸ POLB P06746 5/20 0.49
▸ G6PD P11413 1/20 0.49
▸ L3MBTL1 Q9Y468 2/20 0.48
▸ TSHR P16473 1/20 0.47
▸ THRB P10828 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12417042 0.91 KDM4E (0.58) ALDH1A1KDM4EMAOBKMT2AMEN1
SCHEMBL12417052 0.90 ALDH1A1 (0.55) ALDH1A1KDM4EMAOBKMT2AMEN1
SCHEMBL12417005 0.88 KDM4E (0.54) ALDH1A1KDM4EMAOBKMT2AMEN1
SCHEMBL12417035 0.88 ALDH1A1 (0.54) ALDH1A1KDM4EMAOBKMT2AMEN1
SCHEMBL12417034 0.88 KMT2A (0.56) ALDH1A1KDM4EMAOBKMT2AMEN1
SCHEMBL12417040 0.88 KDM4E (0.54) ALDH1A1KDM4EMAOBKMT2AMEN1
SCHEMBL12417067 0.84 PTGS2 (0.56) ALDH1A1KDM4EKMT2AMEN1MAPT
SCHEMBL12417072 0.84 ALDH1A1 (0.52) ALDH1A1KDM4EMAOBKMT2AMEN1
SCHEMBL12417062 0.83 KMT2A (0.67) ALDH1A1KDM4EKMT2AMEN1MAPT
SCHEMBL12417071 0.83 ALDH1A1 (0.54) ALDH1A1KDM4EKMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110172234-A1 METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2011-07-14 — — US disclosed
US-20110172234-A1 METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2011-07-14 — — US disclosed
US-7915245-B2 Using small molecules as binding ligands, for the recruitment of Fas-associated death domain protein, activation of death-inducing signaling complex, caspase-8, and apoptosis in malignant cells; anticarcinogens, antitumor agents; enhanced cellular differentiation, minimizing cytolysis to healthy cells THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2011-03-29 — — US disclosed
US-7915245-B2 Using small molecules as binding ligands, for the recruitment of Fas-associated death domain protein, activation of death-inducing signaling complex, caspase-8, and apoptosis in malignant cells; anticarcinogens, antitumor agents; enhanced cellular differentiation, minimizing cytolysis to healthy cells THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2011-03-29 — — US disclosed
US-20080214547-A1 METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS UNIVERSITY OF MARYLAND, BALTIMORE 2008-09-04 — — US disclosed
US-20080214547-A1 METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS UNIVERSITY OF MARYLAND, BALTIMORE 2008-09-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214547-A1 METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS BID, BAD, MCL1 ALDH1A1 3768/4885KDM4E 3451/4885MAOB 4398/4885
US-20110172234-A1 METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS BID, BAD, MCL1 ALDH1A1 3768/4885KDM4E 3451/4885MAOB 4398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback